Singapore scientists have demonstrated that the CRISPR-Cas13 editor, delivered through adeno-associated virus (AAV), can effectively target and eliminate RNA viruses in mouse models. The study, published recently in eBioMedicine, specifically focused on the EV-A71 virus, which causes hand, foot, and mouth disease and can lead to severe nervous system complications and death.

The team developed the Cas13gRNAtor bioinformatics pipeline to design CRISPR gRNAs that could effectively cut viral RNA across different viral strains. Their experiments demonstrated that CRISPR-Cas13 treatment significantly reduced the viral burden, with less than 0.1% of viruses remaining in previously infected cells.

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

Importantly, the research revealed that AAV-CRISPR-Cas13 therapy successfully cleared the EV-A71 infection and prevented organ damage and mortality. The results indicate that one dose of CRISPR-Cas13 can make a life-saving difference, prompting the researchers to explore further nucleic acid therapeutics.

This breakthrough opens up a therapeutic development pipeline for antiviral AAV-CRISPR-Cas13 treatment against deadly RNA virus infections. As further therapeutic developments progress, this technology could hold the potential to treat human RNA viruses in clinical settings.